HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Morrisett, J. D. Articles by Kahan, B. D. Search for Related Content PubMed PubMed Citation Articles by Morrisett, J. D. Articles by Kahan, B. D. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 43, 1170-1180, August 2002
Copyright © 2002 by Lipid Research, Inc.

Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients

Joel D. Morrisett^1,*, Ghada Abdel-Fattah^*, Ron Hoogeveen^*, Eddie Mitchell^*, Christie M. Ballantyne^*, Henry J. Pownall^*, Antone R. Opekun^*, Jonathon S. Jaffe, Suzanne Oppermann and Barry D. Kahan

^* The Department of Medicine, Baylor College of Medicine, Houston, Texas
Department of Surgery, University of Texas-Houston Health Science Center, Houston, TX
Wyeth Ayerst Laboratories, Philadelphia, PA

¹ To whom correspondence should be addressed. e-mail: morriset{at}bcm.tmc.edu

Sirolimus (Rapammune^®, rapamycin, RAPA) is a potent immunosuppressive drug that reduces renal transplant rejection. Hyperlipidemia is a significant side effect of sirolimus treatment, and frequently leads to cardiovascular disease. This study was undertaken to determine the repeatability, reversibility, and dose dependence of the plasma lipid and apolipoprotein altering effects of sirolimus, and to elucidate the mechanism by which sirolimus induces hypertriglyceridemia in some renal transplant patients. Six patients with renal allografts maintained on cyclosporine A and prednisone were selected on the basis of their previous hyperlipidemic response to short term (14 days) sirolimus administration. For longer-term treatment, each patient was started on 10 mg/day sirolimus and continued as tolerated for 42 days to reinduce hyperlipidemia. Timed blood samples were analyzed for lipid, apolipoprotein, and sirolimus levels. During sirolimus administration, mean total plasma cholesterol increased from 214 mg/dl to 322 mg/dl (+50%; range 25–92%); LDL-cholesterol levels followed a similar pattern. Mean triglyceride level rose from 227 to 432 mg/dl (+95%; range 9–254%). ApoB-100 concentration rose from 124 to 160 mg/dl (+28%; P < 0.05). ApoC-III level increased from 28.9 to 55.5 mg/dl, +92%; (P < 0.013). These lipid and apolipoprotein changes were found to be repeatable, reversible, and dose dependent. [¹³C₄]palmitate metabolic studies in four patients with hypertriglyceridemia indicated that the free fatty acid pool was expanded by sirolimus treatment (mean = 42.3%). Incorporation of [¹³C₄]palmitate into triglycerides of VLDL, IDL, and LDL was decreased 38.3%, 42,1%, and 38.4%, respectively, by sirolimus treatment of these patients.

These results suggest that sirolimus alters the insulin signaling pathway so as to increase adipose tissue lipase activity and/or decrease lipoprotein lipase activity, resulting in increased hepatic synthesis of triglyceride, increased secretion of VLDL, and increased hypertriglyceridemia.

Abbreviations: CsA, cyclosporine A; FKBP, FK506 binding protein; PFB, pentafluorobenzyl; WAS-#/#, Wyeth Ayerst study patient before/after sirolimus treatment

Supplementary key words rapamycin • triglyceride • cholesterol

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				K. L. Ma, X. Z. Ruan, S. H. Powis, J. F. Moorhead, and Z. Varghese Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2721 - H2728. [Abstract] [Full Text] [PDF]

				P. Anand and P. A. Gruppuso Rapamycin Inhibits Liver Growth during Refeeding in Rats via Control of Ribosomal Protein Translation but Not Cap-Dependent Translation Initiation J. Nutr., January 1, 2006; 136(1): 27 - 33. [Abstract] [Full Text] [PDF]

				J. J. Zimmerman, K. C. Lasseter, H.-K. Lim, D. Harper, S. C. Dilzer, V. Parker, and K. Matschke Pharmacokinetics of Sirolimus (Rapamycin) in Subjects With Mild to Moderate Hepatic Impairment J. Clin. Pharmacol., December 1, 2005; 45(12): 1368 - 1372. [Abstract] [Full Text] [PDF]

				A. Teutonico, P. F. Schena, and S. Di Paolo Glucose Metabolism in Renal Transplant Recipients: Effect of Calcineurin Inhibitor Withdrawal and Conversion to Sirolimus J. Am. Soc. Nephrol., October 1, 2005; 16(10): 3128 - 3135. [Abstract] [Full Text] [PDF]

				J. L. Larsen Pancreas Transplantation: Indications and Consequences Endocr. Rev., December 1, 2004; 25(6): 919 - 946. [Abstract] [Full Text] [PDF]

				C. E. Freise, S.-M. Kang, S. Feng, R. Hirose, and P. Stock Excellent Short-term Results With Steroid-Free Maintenance Immunosuppression in Low-Risk Simultaneous Pancreas-Kidney Transplantation Arch Surg, October 1, 2003; 138(10): 1121 - 1126. [Abstract] [Full Text] [PDF]

				Y. M. Cho, K. S. Park, H. S. Jung, H. J. Jeon, C. Ahn, J. Ha, S. J. Kim, B. D. Rhee, S. Y. Kim, and H. K. Lee High Incidence of Tacrolimus-Associated Posttransplantation Diabetes in the Korean Renal Allograft Recipients According to American Diabetes Association Criteria Diabetes Care, April 1, 2003; 26(4): 1123 - 1128. [Abstract] [Full Text] [PDF]